Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy (Q35917421)

11 August 2017

1 reference

title

Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy (English)

1 reference

11 August 2017

0 references

0 references

cytomegaloviral disease

1 reference

1

Mark R Schleiss

1 reference

11 August 2017

2

Michael A McVoy

1 reference

11 August 2017

1 June 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

1 reference

11 August 2017

2

1 reference

11 August 2017

3

1 reference

11 August 2017

389-403

1 reference

The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Vaccination against cytomegalovirus, the changeling demon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

The role of cytomegalovirus-encoded homologs of G protein-coupled receptors and chemokines in manipulation of and evasion from the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Neonatal cytomegalovirus infections due to blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Cytomegalovirus infection of extremely low-birth weight infants via breast milk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Evaluation of cytomegalovirus infections transmitted via breast milk in preterm infants with a real-time polymerase chain reaction assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Prenatal indicators of congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Recent advances in the therapy and prevention of CMV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Antiviral therapy for cytomegalovirus infections in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

The 2001 Garrod lecture. The treatment of cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Antiviral drug resistance in human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

DNA encapsidation as a target for anti-herpesvirus drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Ganciclovir--a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Placental transfer of ganciclovir in a woman with acquired immunodeficiency syndrome and cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

Ganciclovir Treatment of Congenital Cytomegalovirus Infection: A report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.3.389

21 January 2018

Identifiers

DOI

10.1586/14787210.2.3.389

1 reference

11 August 2017

1 reference

PubMed ID

15482204